Long-term Impact of Oral Azithromycin Taken by Gambian Women During Labor on Prevalence and Antibiotic Susceptibility of Streptococcus pneumoniae and Staphylococcus aureus in Their Infants: Follow-up of a Randomized Clinical Trial

Clin Infect Dis. 2018 Sep 28;67(8):1191-1197. doi: 10.1093/cid/ciy254.

Abstract

Background: Oral azithromycin given to women in labor decreases maternal and neonatal bacterial carriage but increases azithromycin-resistant bacteria during at least 4 weeks following the intervention. We assessed the prevalence of bacterial carriage and azithromycin resistance 12 months after treatment among study infants.

Methods: Nasopharyngeal swabs (NPSs) were collected between November 2014 and May 2015 from children aged 11-13 months whose mothers had received azithromycin or placebo during labor. Streptococcus pneumoniae and Staphylococcus aureus were isolated using conventional microbiological methods. Antibiotic susceptibility was determined by disk diffusion and confirmed by Etest or VITEK-2.

Results: NPSs were collected from 461 children. The prevalence of S. pneumoniae and S. aureus was similar between children from the azithromycin and placebo arms (85.0% vs 82.1%; odds ratio [OR], 1.23 [95% confidence interval {CI}, .73-2.08] for S. pneumoniae and 21.7% vs 21.3%; OR, 1.02 [95% CI, .64-1.64] for S. aureus). Prevalence of azithromycin-resistant S. pneumoniae was similar in both arms (1.8% vs 0.9% in children from the azithromycin and placebo arms, respectively; OR, 2.10 [95% CI, .30-23.38]); resistance to other antibiotics was also similar between arms. For S. aureus, there was no difference in azithromycin resistance between children in the azithromycin (3.1%) and placebo (2.6%) arms (OR, 1.22 [95% CI, .35-4.47]) or resistance to any other antibiotics.

Conclusions: The higher prevalence of S. aureus azithromycin resistance observed among women treated during labor and their babies 4 weeks after treatment had waned 12 months after delivery. Azithromycin intervention did not induce other antibiotic resistance to S. pneumoniae or S. aureus.

Clinical trials registration: NCT01800942.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / therapeutic use*
  • Carrier State / drug therapy
  • Carrier State / microbiology
  • Drug Resistance, Bacterial*
  • Female
  • Follow-Up Studies
  • Gambia
  • Humans
  • Infant
  • Labor, Obstetric
  • Long Term Adverse Effects
  • Male
  • Maternal Exposure
  • Microbial Sensitivity Tests
  • Nasopharynx / microbiology
  • Pregnancy
  • Prevalence
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus / drug effects*
  • Streptococcus pneumoniae / drug effects*
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Azithromycin

Associated data

  • ClinicalTrials.gov/NCT01800942